

## Competition Law Forum

## 13th Annual BIICL Mergers and Markets Conference

Sponsored by





25 May 2016, 14.00-18.10 BIICL, Charles Clore House, 17 Russell Square, London WC1B 5JP

## **Programme**

Introduction by Dr. Liza Lovdahl Gormsen (Director, Competition Law Forum and Senior Research Fellow)

Panel 1	14.00-15.10 Review of the year and current issues
	Chair: Simon Priddis - Partner, Freshfields Bruckhaus Deringer
	Daniel Beard QC - Monckton Chambers
	Sheldon Mills - Senior Director, Mergers, Competition and Markets Authority
	Topics to be discussed:
	Legal certainty and institutional effectiveness in merger control
	An increasing information burden for merging parties?
	Phase I counterfactuals: time to update the guidelines?
	Phase 2 referrals within a single integrated agency: independence and efficiencies
	• Remedies at Phase 1 and Phase 2: scope for a new approach?
	15.10-15.30 Coffee break
Panel 2	15.30-16.40 Maximising your chance for success at phase I
	Chair: Adrian Majumdar - Partner, RBB Economics

	Edward Anderson - Head of Commercial & Competition Law, Sainsbury's
	Kate Collyer - Deputy Chief Economic Adviser, Competition and Markets Authority
	Martin McElwee - Partner, Freshfields Bruckhaus Deringer
	Topics to be discussed:
	• Engage or enrage: how best to communicate with the CMA in pre-notification and at Phase I.
	Poll-itics: where does the CMA currently stand on surveys?
	<ul> <li>Shifting sands: What is the CMA's latest view on screens in local mergers?</li> </ul>
	<ul> <li>In documents we trust: what evidence carries the most weight at Phase I?</li> </ul>
	Too big to clear: when is fast-track best?
	16.40-17.00 Coffee break
Panel 3	17.00-18.10 The 'market' for market investigations
	Chair: Rod Carlton - Partner, Freshfields Bruckhaus Deringer
	Phillip Evans - Deputy Panel Chair and Inquiry Chair, Competition and Markets Authority
	Robin Finer - Head of Department, Competition, Financial Conduct Authority
	Bojana Ignjatovic - Partner, RBB Economics
	Topics to be discussed:
	• Is there a problem on the demand side – do politicians and consumers understand the 'service'?
	Are there supply side concerns – co-operation vs. competition among the CMA and sector regulators?
	Does the incumbent (CMA) offer a superior service? Experience from recent cases
	The new entrant's offering (FCA): a 'stripped down' service, but better value?
	Do we need service innovations at the 'diagnosis' stage: evidence gathering and analysis?
	Are we seeing useful innovation at the 'prescription' stage: remedy selection and pre-testing?
	Challenges and opportunities for the authorities as this 'market' evolves

18.10-19.00 Reception